Morgan Stanley upgraded shares of Sanofi (NYSE:SNY) from an equal rating to a weight rating in a research note published on Friday, The Fly reports.
SNY has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Sanofi from a hold rating to a buy rating and set a $47.00 target price for the company in a research report on Thursday, August 29th. Sanford C. Bernstein began coverage on shares of Sanofi in a research report on Tuesday, September 3rd. They issued an outperform rating and a $52.00 target price for the company. Jefferies Financial Group reiterated a buy rating on shares of Sanofi in a research report on Thursday, August 29th. TheStreet upgraded shares of Sanofi from a c+ rating to a b- rating in a research report on Friday, June 21st. Finally, JPMorgan Chase & Co. reiterated a neutral rating on shares of Sanofi in a research report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Sanofi presently has a consensus rating of Buy and a consensus price target of $49.67.
NYSE:SNY opened at $46.21 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The company has a fifty day moving average of $43.19 and a two-hundred day moving average of $42.88. The stock has a market capitalization of $116.34 billion, a PE ratio of 14.76, a P/E/G ratio of 2.41 and a beta of 0.67. Sanofi has a fifty-two week low of $40.00 and a fifty-two week high of $46.60.
In other Sanofi news, major shareholder Sanofi bought 93,750 shares of Sanofi stock in a transaction dated Monday, July 22nd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $1,500,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Fisher Asset Management LLC grew its holdings in shares of Sanofi by 2.2% in the second quarter. Fisher Asset Management LLC now owns 16,868,423 shares of the company’s stock valued at $729,897,000 after purchasing an additional 367,961 shares during the period. FMR LLC grew its holdings in shares of Sanofi by 1.9% in the first quarter. FMR LLC now owns 9,233,558 shares of the company’s stock valued at $408,862,000 after purchasing an additional 175,580 shares during the period. Morgan Stanley grew its holdings in shares of Sanofi by 34.1% in the second quarter. Morgan Stanley now owns 3,145,435 shares of the company’s stock valued at $136,104,000 after purchasing an additional 800,612 shares during the period. Lazard Asset Management LLC grew its holdings in shares of Sanofi by 47,594.3% in the first quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock valued at $105,595,000 after purchasing an additional 2,379,716 shares during the period. Finally, Northern Trust Corp boosted its stake in Sanofi by 2.5% during the second quarter. Northern Trust Corp now owns 2,275,495 shares of the company’s stock worth $98,461,000 after buying an additional 56,394 shares during the period. 7.04% of the stock is owned by hedge funds and other institutional investors.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: How is inflation measured?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.